Brokers Issue Forecasts for PVLA FY2029 Earnings

Palvella Therapeutics (NASDAQ:PVLA) – Stock analysts at HC Wainwright issued their FY2029 earnings estimates for shares of Palvella Therapeutics in a research report issued to clients and investors on Friday, January 3rd. HC Wainwright analyst A. Fein forecasts that the company will earn ($0.69) per share for the year. HC Wainwright has a “Buy” rating and a $38.00 price target on the stock.

Separately, Cantor Fitzgerald started coverage on shares of Palvella Therapeutics in a research report on Wednesday, December 18th. They set an “overweight” rating on the stock.

Palvella Therapeutics Trading Up 10.4 %

Shares of PVLA stock opened at $13.25 on Monday. The stock has a market cap of $17.49 million, a price-to-earnings ratio of -1.10 and a beta of 0.61. Palvella Therapeutics has a 12 month low of $6.20 and a 12 month high of $22.32.

Insider Buying and Selling

In related news, Director George M. Jenkins bought 4,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 18th. The stock was purchased at an average price of $12.93 per share, for a total transaction of $51,720.00. Following the acquisition, the director now owns 180,671 shares of the company’s stock, valued at approximately $2,336,076.03. This trade represents a 2.26 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 6.39% of the company’s stock.